“We attend ASCO regularly and never knew we could get help in ensuring the presented clinical data was optimally received by oncologists or how competitive announcements could potentially have an adverse impact. MDOutlook gave us new insights into projected usage rates of our therapy and helped us recalibrate our market share targets in the major global markets we operate in.”
-Major Global Biopharma Organization with Growing Oncology Portfolio
MDOutlook assists pharma and life sciences organizations in maximizing results at major industry conferences, and achieved demonstrable success for one client at 2016 ASCO.
A major international pharma company with a growing oncology portfolio was ready to make a significant data announcement about a new treatment in dual checkpoint inhibitor antibodies in SCLC. They needed an impact assessment of current treatments as well as other data announcements scheduled for the category at the conference.
In only 4 weeks, MDOutlook turned around an integrated global research study of live panel discussions and a survey of pre-screened oncologists and physicians in multiple disciplines with high patient volumes, specialized knowledge and experience with SCLC treatments in the US, and key EU and international markets.
As a result, we provided immediate, actionable insights on how current treatments and new data developments at ASCO in the SCLC category would affect this company’s announcements about its new therapy entrant in the space. Based on our analysis and report, the company was able to project future physician usage of its treatment around the world and better calibrate market share growth globally of its treatment versus competitor treatments over time.
Give us the opportunity to deliver the same results for you before your next cancer conference by contacting the team at MDOutlook today.
We offer custom and syndicated programs for ASCO, EHA, ESMO and ASH, and custom research at many other cancer conferences.